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Abstract
Although most patients with Clostridium difﬁcile infection (CDI) can be managed effectively with discontinuation of prescribed antibiotics
and additional treatment with oral metronidazole or vancomycin, up to 25% experience disease recurrence, usually within 30 days of
treatment. Failure to mount a systemic anti-toxin antibody response differentiates patients with CDI and recurrent CDI from symptom-
less carriers of toxinogenic C. difﬁcile. The immunological senescence that accompanies ageing may lead to impaired immune responses
to C. difﬁcile and contribute to the signiﬁcant association between advancing age and increased risk of CDI recurrence. Inadequate
immunity may also explain why previous episodes of recurrence constitute a signiﬁcant risk factor for further CDI recurrences. Other
risk factors for recurrent CDI include concurrent use of antibiotics for non-C. difﬁcile infections (which perpetuate the loss of coloniza-
tion resistance), proton-pump inhibitors, and other gastric acid anti-secretory medications, prolonged hospitalization, and severe under-
lying illness (as reﬂected by a high Horn index score). Prominent risk factors have been examined to develop and validate a clinical
prediction tool for recurrent CDI, with three factors (age >65 years, severe underlying disease (by the Horn index score), and contin-
ued use of antibiotics for non-CDI infections) being highly predictive of CDI recurrence. Such simple clinical prediction rules have the
potential to identify patients at high risk of recurrent CDI, and can alert the treating physician to the need for prompt recognition, con-
ﬁrmatory diagnosis and treatment with regimens ideally designed to mitigate the risk of subsequent recurrences.
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Introduction
First identiﬁed in 1935, Clostridium difﬁcile emerged as an
important pathogen in the late 1970s, following the introduc-
tion of broad-spectrum antibiotics [1]. Because most patients
experienced few complications at that time [2], C. difﬁcile
infection (CDI) was generally regarded as a mildly troublesome
side effect of antibiotic use. The marked increase in the inci-
dence and severity of CDI seen in the past decade means that
CDI is now viewed as a serious healthcare-associated infection
linked to high rates of morbidity and mortality [3–5].
Most patients who develop CDI today require speciﬁc anti-
biotic therapy to eliminate C. difﬁcile from the colon, but
nonetheless some can be managed conservatively. This entails
stopping all antimicrobial therapy that may have been impli-
cated in the onset of diarrhoea, requesting stool tests for
C. difﬁcile or its toxins, monitoring patients’ progress, and then
starting speciﬁc antibiotic therapy if symptoms and signs of
CDI worsen or persist. Patients with mild to moderate CDI
generally receive ﬁrst-line treatment with oral metronidazole;
oral vancomycin is often reserved for more severe cases
[6,7]. These antibiotics are considered to be effective for the
treatment of a ﬁrst episode of CDI, although metronidazole is
coming under increased scrutiny because of growing reports
of treatment failure. Prior to 2000, reported treatment failure
rates were <10%, whereas failure rates approaching 20% have
been recorded for metronidazole since 2000 [8].
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Irrespective of which antibiotic is used as ﬁrst-line therapy
for an initial acute episode of CDI, a signiﬁcant minority of
patients experience disease recurrence following cessation of
therapy. The evidence suggests that rates of CDI recurrence
are increasing from those seen in the 1980s and 1990s [8], and
that the emergence of hypervirulent strains of C. difﬁcile, such
as ribotype 027, may have been a contributory factor. Data
from a retrospective review of patient records in Canada
showed that, coincident with the emergence of the 027 strain
outbreak in Quebec, the 60-day probability of CDI recurrence
with metronidazole increased signiﬁcantly from 20.8% (between
1991 and 2002) to 47.2% (in 2003–2004; p <0.001), suggesting
a possible link with the 027 strain [9]. Among patients infected
with the 027 strain of C. difﬁcile in the two randomized con-
trolled trials (RCTs) that compared ﬁdaxomicin with vancomy-
cin, rates of recurrence were signiﬁcantly higher than those
seen in patients infected with other strains (27.4% vs. 16.6%,
respectively; p 0.002) [10]. In fact, infection with the 027 strain
emerged as a signiﬁcant risk factor for recurrence in a multivari-
ate analysis of these data (OR 1.57; 95% CI 1.01–2.45; p 0.046)
[10]. Data from the individual trials showed that the signiﬁcant
reductions in recurrence observed in the ﬁdaxomicin treatment
arm vs. vancomycin occurred primarily in patients infected with
strains of C. difﬁcile other than 027 [4,11]. There was no signiﬁ-
cant difference in rates of recurrence between the two treat-
ments for patients infected with the 027 strain of C. difﬁcile
[4,11]. Overall, the results from these trials showed that, in the
vancomycin comparator arm, c. 25% of patients experienced
recurrent CDI in the 30-day follow-up period [4,11]. Such
recurrence rates are similar to those observed for metronida-
zole (19%) and vancomycin (18%) in an RCT of the toxin-bind-
ing agent tolevamer [12], and rates of 23% and 32%,
respectively, in the antibiotic treatment arms of RCTs of
adjunctive anti-toxin monoclonal antibody therapy [13].
Thus, recurrent CDI represents one of the most difﬁcult
and increasingly common challenges that we face in the man-
agement of CDI. This problem is exacerbated by the dramatic
and sustained increase in the incidence of primary CDI in both
North America and many parts of Europe [6,14]. This review
will look at the factors that predispose patients to CDI recur-
rence, examine risk factor indices that might be used to
improve CDI management, and evaluate the practicalities of
applying such risk factor indices in the clinical setting.
Pathophysiology and Frequency of CDI
Recurrence
The key stages in the pathogenesis of CDI are illustrated in
Fig. 1. CDI is most likely to develop when a patient is exposed
to either the bacterium or its spores and, at the same time,
the normal colonic microﬂora is disturbed following a course
of antimicrobial therapy. Depletion of Bacteroides and other
colonic bacteria leads to a decrease in the overall diversity of
the colonic microbiota [15,16] and the subsequent loss of col-
onization resistance. This allows opportunistic infection with
C. difﬁcile to ﬂourish [1,17] and, where richness of the colonic
microﬂora is markedly depleted, for CDI to recur [16]. Pri-
mary infection is facilitated by the fact that C. difﬁcile is resis-
tant to many commonly used antibiotics, with the exception
of those used to treat CDI [18]. CDI develops in patients
who acquire toxinogenic strains of C. difﬁcile, which typically
produce both toxin A (encoded by TcdA) and toxin B
(encoded by TcdB), and who lack protective immunity. The
evidence suggests that patients who become colonized with
toxinogenic C. difﬁcile and are also able to mount an adequate
systemic immune response to C. difﬁcile and its toxins are less
likely to develop CDI [14]. Many subjects colonized by toxi-
nogenic strains of C. difﬁcile remain asymptomatic, and this is
associated with high serum levels of speciﬁc anti-toxin IgG
antibodies, which are lacking in those with symptomatic CDI
[19]. Furthermore, when symptomatic patients mount an anti-
toxin immune response early in the course of infection with
toxinogenic C. difﬁcile, they become less likely to experience
recurrent CDI [14].
Today, patients with CDI generally receive treatment with
either a 10–14-day course of oral metronidazole or vanco-
mycin, depending on the severity of the disease [6]. The
FIG. 1.Outcomes following exposure to toxinogenic strains of Clostrid-
ium difﬁcile [1]. Adapted, with permission, from the Annual Review of Medi-
cine, Volume 49ª 1998 by Annual Reviews http://www.annualreviews.org.
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majority of patients will respond to such therapy with com-
plete resolution of symptoms within 7–10 days [1,6,20,21].
However, as we have seen, up to 25% of patients will expe-
rience disease recurrence within 30 days following cessation
of treatment with metronidazole or vancomycin [4,12,13]
(Fig. 2). Recurrence of CDI usually manifests as diarrhoea
and other signs and symptoms of CDI, and is conﬁrmed by
the recurrence or persistence of a positive stool test result
for C. difﬁcile or its toxins [6].
Most recurrences occur within the ﬁrst 30 days of com-
pleting a course of anti-CDI antibiotic therapy, and may arise
from a resumption of the primary infection (relapse) or from
a new exposure to C. difﬁcile (re-infection). The term ‘recur-
rent CDI’ will be used to denote either relapse or re-infec-
tion, as the diagnosis and management of both forms of
recurrence are similar, and the two mechanisms are rarely
differentiated in clinical practice. Relapse and re-infection
may occur with similar frequencies [22,23], although contin-
ued exposure to C. difﬁcile is necessary for re-infection to
occur. Ironically, as metronidazole and vancomycin both alter
the colonic microﬂora, either drug may perpetuate a loss of
colonization resistance to C. difﬁcile, and may therefore pre-
dispose to recurrence [1]. Resistance to metronidazole and
vancomycin has, to date, not been identiﬁed as a signiﬁcant
clinical problem in CDI management, and is not therefore
considered to be a contributor to CDI recurrence [24].
However, it is important to note in this context that stan-
dard antibiotic therapy for CDI is ineffective against C. difﬁcile
spores in the gut [25].
Recurrent CDI places a heavy burden on patients, from
increased morbidity and diminished quality of life associated
with repeated episodes of diarrhoea [26]. Furthermore,
mortality occurs in recurrent CDI as it does in primary
infection. Patients with recurrent CDI also serve as a reser-
voir of infection that can lead to secondary infection in other
vulnerable patients [24]. Thus, reducing the risk of recurrent
CDI has the potential to improve patients’ quality of life
through reductions in CDI-associated morbidity and mortal-
ity as well as by reducing the risk of person-to-person trans-
mission [4]. Reducing recurrent CDI can also lead to
commensurate reductions in inpatient and outpatient costs
associated with treating additional episodes of CDI and from
the need to isolate patients.
Risk Factors for Recurrent CDI
Once patients have experienced one recurrence of CDI,
they are at signiﬁcantly increased risk of further recurrences
[27]. In fact, studies have shown that the risk of recurrence
more than doubles after two or more recurrences [28,29]
(Fig. 2). Some patients experience multiple recurrences, lead-
ing to repeated bouts of diarrhoea and long courses of anti-
biotic therapy [27]. Continued disruption of the normal
colonic microﬂora by repeated cycles of antibiotic therapy
used to treat recurrent CDI perpetuates the risk of repeated
recurrences.
Efforts to discover why some patients are at greater risk of
experiencing CDI recurrence have identiﬁed a number of pre-
disposing factors in addition to prior recurrence. The risk of
recurrence increases with increasing age, and patients aged
‡65 years are at signiﬁcantly greater risk of recurrent CDI
than younger patients [9,27]. One study showed a two-fold
increase in recurrence rates for those aged ‡64 years as com-
pared with those aged <64 years [9] (Fig. 3). A systematic
FIG. 2. Frequency of recurrent Clostridium difﬁcile infection (CDI)
following an initial episode and ﬁrst and second recurrence
[4,12,13,28,29].
FIG. 3. The association between advancing age and risk of recurrent
Clostridium difﬁcile infection (CDI) (data from 2003 to 2004 during an
outbreak of severe C. difﬁcile infection in Quebec, Canada) [9].
Reproduced, with permission, from Oxford University Press.
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analysis of 12 studies (reﬁned from a total of 1215 studies ini-
tially identiﬁed), which included 1382 patients with CDI, has
conﬁrmed these ﬁndings, and shown that older age
(‡65 years) is signiﬁcantly associated with increased risk of
recurrent CDI (p 0.0012) [30]. This systematic analysis, for
which rigorous eligibility criteria were used, also showed that
patients were at increased risk of recurrent CDI if they were
receiving concomitantly administered non-C. difﬁcile antibiotics
following a diagnosis of CDI, or were receiving gastric acid-
suppressing medications, especially proton-pump inhibitors
[30]. However, in this systematic analysis, potential risk fac-
tors were evaluated only if studied in at least three indepen-
dent publications that met the quality inclusion criteria. For
this reason, several prominent risk factors for recurrent CDI
were unable to be studied, e.g. underlying disease severity (as
measured by the Horn index) and anti-toxin immune
response.
Given that the development of a protective antibody-med-
iated immune response to C. difﬁcile toxins appears to be
critical with regard to whether or not patients become
symptomless carriers of C. difﬁcile or develop symptomatic
CDI, the immune status of the host would be expected to
inﬂuence susceptibility to CDI recurrence. Studies have
indeed shown an association between serum IgG anti-toxin
antibody responses at day 12, the point at which speciﬁc
anti-CDI antibiotic therapy will usually be discontinued, and
protection against recurrent CDI (Fig. 4) [31]. This suggests
that an impaired immune response to C. difﬁcile toxins also
contributes to an increased risk of disease recurrence.
Hospitalization constitutes a major risk factor for the
acquisition of CDI, as it brings together multiple risk factors,
including an increasingly elderly population, exposure to anti-
biotics, and an environment contaminated by C. difﬁcile
spores. Prolonged hospital stay is associated with the risk of
developing recurrent CDI [26,32]; this ﬁnding was conﬁrmed
in a recent retrospective analysis of 1678 patients with CDI
that also found past hospital exposure and, especially, previ-
ous admission to a gastrointestinal ward to be signiﬁcant
predictors of ﬁrst recurrence [33]. Patients are also at
increased risk of recurrent CDI if they have severe or extre-
mely severe underlying disease, as indicated by a modiﬁed
Horn index score of 3 or 4 [34]. Speciﬁc comorbidities that
have been found to be associated with an increased risk of
recurrent CDI include a history of chronic renal impairment
[35], as patients are often in poor health and require pro-
longed hospitalization, a compromised immune system [36],
and inﬂammatory bowel disease [37]. Infection with the hy-
pervirulent 027 strain of C. difﬁcile may also, as discussed
earlier, convey an increased risk of recurrence [10], although
this has not been borne out in all recent analyses of risk fac-
tors for CDI recurrence [33].
Validation of a Clinical Prediction Rule for
Recurrent CDI
Predicting which patients, or patient subsets, may experience
recurrent CDI would be clinically useful. On the basis of a
prospective study of 44 patients with CDI (derivation cohort),
we undertook a multivariate logistic regression analysis to
develop a clinical prediction rule for recurrent CDI, and then
prospectively evaluated the performance of the rule in an
independent cohort of hospitalized patients with CDI (valida-
tion cohort). Age >65 years, the presence of severe underly-
ing disease (modiﬁed Horn index score of 3 or 4) and the use
of additional antibiotics after discontinuation of CDI therapy
emerged as factors that are independently associated with an
increased risk of recurrence (Table 1) [34]. All three of these
had previously been identiﬁed as risk factors for recurrent
CDI, either in the systematic analysis described above or in
another study [38]. The clinical prediction rule effectively
FIG. 4. Association between serum IgG antibody response to Clos-
tridium difﬁcile toxins and protection against recurrent C. difﬁcile
infection (CDI) [31].
TABLE 1. Clinical prediction rule for recurrent Clostridium
difﬁcile infection [34]
Risk factor Score
Age >65 years 1
Severe underlying disease (Horn index score of 3 or 4)a 1
Additional antibiotic use 1
Add one point for each risk factor present to
determine score (range 0–3)
aThe Horn index rates the severity of underlying disease into one of four cate-
gories on the basis of clinical judgement: 1 = mild (single mild illness); 2 = mod-
erate (more severe illness but uncomplicated recovery expected); 3 = severe
(major complications or multiple conditions requiring treatment); 4 = fulminant
(catastrophic life-threatening illness).
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discriminated between patients with and without recurrent
CDI, with 77.3% and 71.9% of patients in the derivation and
validation cohorts, respectively, being correctly classiﬁed as
having a single episode of CDI vs. recurrence (Table 2) [34].
Although patients who fail to mount a protective antibody-
mediated response to C. difﬁcile toxins are at increased risk of
CDI recurrence [31], the inclusion of day 12 anti-toxin A
serum IgG antibody measurements did not increase diagnostic
accuracy in the derivation cohort, and so was not used in the
ﬁnal prediction rule [34]. Moreover, to be of clinical use, real-
time measurement of antibody levels would be required,
which is not feasible at the present time.
The clinical prediction rule described above is believed to
be a useful contribution to clinical practice. However, it has
some important limitations, including small sample size. In a
recent systematic review of prediction tools for unfavourable
outcome in CDI that included recurrent disease, Abou
Chakra et al. [39] argue the case for the development of evi-
dence-based tools through appropriate prospective cohorts
in preference to empirically developed rules, but also stress
the need for further validation of existing tools. The clinical
prediction rule described here certainly merits further valida-
tion in a larger cohort of patients, as this would help to
improve its precision and robustness.
Using Clinical Prediction Rules to Guide
Interventions
The prediction rule for recurrent CDI described above
appears to be simple, reliable, and accurate [30]. In both the
derivation and validation cohorts, there was a stepwise
increase in the percentage of patients experiencing recurrent
CDI as the score increased from 0 to a maximum of 3. Thus,
in clinical practice, it has potential to discriminate between
patients at high risk of developing recurrent CDI from those
at low risk. By heightening awareness of a risk of recurrent
CDI, it can be used to alert the treating physician and the
patient to the need for prompt recognition, conﬁrmatory
diagnosis, and treatment, should recurrence develop. Patients
who meet the criteria for a high risk of CDI recurrence may
beneﬁt from interventions with the potential to mitigate the
risk of recurrence, such as ﬁdaxomicin [4,11]. Where clini-
cally possible, other preventive measures might include
avoidance of concomitant antibiotic therapy, judicious choice
of lower-risk agents where concomitant antibiotics are
needed, and the avoidance of acid anti-secretory medications
such as proton-pump inhibitors.
As we have seen, a simple and validated clinical prediction
rule can be used to identify patients at risk of recurrent
CDI. Validated prediction tools would be equally beneﬁcial in
identifying patients at risk of primary CDI, as well as those
at risk of severe disease and adverse outcomes. Identifying
patients at high risk of primary CDI is especially important at
a time of rising incidence, and can be used to test novel pre-
ventive strategies and interventions. Validated prediction
tools are also needed for severe or complicated CDI to
inform decisions on antibiotic choice for CDI therapy.
Similarly to the clinical prediction rule for recurrent CDI,
a prospective cohort study has identiﬁed underlying disease
severity (Horn index score) as an independent predictor of
acquisition of nosocomial CDI [38]. Among hospitalized
patients receiving antibiotic therapy and expected to stay in
hospital for ‡2 days, the probability of acquiring CDI was
27% in those with a Horn index score of 3 or 4 (severe or
fulminant underlying disease), as compared with only 4% in
those with scores of 1 or 2 [38].
Several clinical factors have been linked to CDI of increased
severity and adverse clinical sequelae, with older age again
emerging as an important risk factor [5,7]. Thus, advancing
age is predictive of acquisition of primary CDI, the develop-
ment of severe, complicated CDI, and increased risk of recur-
rence. Factors that are strongly suggestive of severe CDI
include an elevated peripheral white blood cell count
(>15, 000 cells/lL), with counts above 50, 000 cells/lL being
considered a warning of likely mortality [40], and a rising
serum creatinine level [41], which may be indicative of severe
diarrhoea, dehydration, and reduced renal function [7].
Although further prospective studies are needed to con-
ﬁrm the utility of currently developed clinical prediction
rules, such tools will be increasingly important in helping to
identify at-risk patients, so that care can be tailored for indi-
vidual patients as additional preventive and treatment options
become available.
TABLE 2. Risk of recurrent Clostridium difﬁcile infection





n = 44; 50%
recurrence
Validation cohort
n = 64; 20%
recurrence
n % n %
0 0/7 0 0/9 0
1 5/15 33.3 6/36 16.7
2 10/14 71.4 5/16 31.3
3 7/8 87.5 2/3 66.7
Patients with scores ‡2 were classiﬁed as being at high risk of recurrent CDI.
The point estimate of the accuracy of a score ‡2 for predicting recurrence is
71.9% (95% CI 59.2–82.4%) [34]. Other point estimates of performance include
a sensitivity of 53.8%, a speciﬁcity of 76.5%, a positive predictive value of 36.8%,
and a negative predictive value of 86.7% [34].
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Recurrent CDI affects up to one-quarter of patients who
respond to initial CDI therapy with metronidazole or vanco-
mycin, and is the most common management problem with
current treatments. Identifying patients at high risk of CDI
recurrence would allow treating physicians to intervene
more promptly and, possibly, more effectively. Several
patient risk factors for recurrent CDI have been identiﬁed,
and have led to the development of a simple, validated, clini-
cal prediction tool for recurrent CDI. Similar prediction
tools for identifying primary CDI and severe CDI are in
development. Further validation studies and, possibly, the
incorporation of additional criteria can help to strengthen
these tools and improve their diagnostic accuracy. Applying
such prediction tools in clinical practice will allow for the
rational application of interventions that can help to lower
recurrence rates and, in the longer term, eventually prevent
the development of primary, severe and complicated CDI.
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